Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia

Critical Care Medicine

Volumn 24, Issue 4, 1996, Pages 584-589

  Gordon, Bruce R ^a,b   Parker, Thomas S ^a   Levine, Daniel M ^a   Saal, Stuart D ^a   Wang, John C L ^a   Sloan, Betty Jane ^a   Barie, Philip S ^a   Rubin, Albert L ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b ROGOSIN INSTITUTE   (United States)

Author keywords

cholesterol; cytokines; endotoxin; high density lipoprotein; infection; intensive care; lipoproteins; low density lipoprotein; shock; triglycerides; tumor necrosis factor

Indexed keywords

ENDOTOXIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CRITICAL ILLNESS; ENDOTOXEMIA; HUMAN; HYPOLIPEMIA; INTENSIVE CARE; LIPID BLOOD LEVEL; MORTALITY; PRIORITY JOURNAL; SHOCK;

ADULT; AGED; ANALYSIS OF VARIANCE; APOLIPOPROTEINS; CRITICAL ILLNESS; ENDOTOXINS; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOXEMIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030006124     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199604000-00006     Document Type: Article

References (43)

1. Alvarez C, Ramos A: Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986;32:142-145
2. Lees RS, Fiser RH Jr, Beisel WR, et al: Effects of an experimental viral infection on plasma lipid and lipoprotein metabolism. Metabolism 1972; 21:825-833
3. Budd D, Ginsberg H: Hypocholesterolemia and acute myelogenous leukemia. Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 1986; 58:1361-1365
4. Muller CP, Trilling B, Steinke B: The prognostic significance of total serum cholesterol in patients with Hodgkin's disease. Cancer 1992; 69:1042-1046
5. Muller CP, Wagner AU, Maucher C, et al: Hypocholesterolemia, an unfavorable feature of prognostic value in chronic myeloid leukemia. Eur J Haematol 1989; 43:235-239
6. Werner M, Odenthal D: Serum protein changes after gastrectomy as a model of acute phase reaction. J Lab Clin Med 1967; 70:302-310
7. Werner M, Cohnen G: Changes in serum proteins in the immediate postoperative period. Clin Sci 1969; 36:173-184
8. Coombes EJ, Shakespeare PG, Batstone GF: Lipoprotein changes after burn injury in man. J Trauma 1980; 20:971-975
9. Verdery RB, Goldberg AP: Hypocholesterolemia as a predictor of death: A prospective study of 224 nursing home residents. J Gerontol 1991; 46: M84-M90
10. Noel MA, Smith TK, Ettinger WH: Characteristics and outcomes of hospitalized older patients who develop hypocholesterolemia. J Am Geriatr Soc 1991; 39: 455-461
11. Jacobs D, Blackburn H, Higgins M, et al: Report of the conference on low blood cholesterol: Mortality associations. Circulation 1992; 86:1046-1060
12. Miller NE, La Ville A, Crook D: Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 1985; 314: 109-111
13. Freudenberg MA, Bog-Hansen TC, Back U, et al: Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. Infect Immun 1980; 28:373-380
14. Ulevitch RJ, Johnston AR, Weinstein DB: New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67: 827-837
15. Harris HW, Grunfeld C, Feingold KR, et al: Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91:1028-1034
16. Gallay P, Heumann D, Le Roy D, et al: Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci USA 1993; 90:9935-9938
17. Tobias PS, Soldau K, Ulevitch RJ: Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989; 264: 10867-10871
18. Wright SD, Ramos RA, Tobias PS, et al: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433
19. Schumann RR, Leong SR, Flaggs GW, et al: Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429-1431
20. Mathison JC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of Gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81:1925-1937
21. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, et al: Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990; 58:2375-2382
22. Baumberger C, Ulevitch RJ, Dayer JM: Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 1991; 59: 378-383
23. Levine DM, Parker TS, Donnelly TM, et al: In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90:12040-12044
24. Hubsch AP, Powell FS, Lerch PG, et al: A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23
25. Donnelly TM, Kelsey SF, Levine DM, et al: Control of variance in experimental studies of hyperlipidemia using the WHHL rabbit. J Lipid Res 1990; 32: 1089-1098
26. 2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982; 28:1379-1388
27. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502
28. Levine DM, Sloan BJ, Donner JE, et al: Automated measurement of Lp(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992; 22:173-178
29. Parker TS, Levine DM, Chang JCC, et al: Reconstituted high density lipoprotein neutralizes Gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63:253-258
30. Bone RC: Sepsis, the sepsis syndrome, multi-organ failure: A plea for comparable definitions. Ann Intern Med 1991; 114:332-333
31. Brown SA, Hutchinson R, Morrisett J, et al: Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993; 13: 1139-1158
32. Maeda S, Abe A, Seishima M, et al: Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78:145-150
33. Munford RS, Hall CL, Lipton JM, et al: Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest 1982; 70:877-888
34. Tobias PS, Ulevitch RJ: Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). J Immunol 1983; 131:1913-1916
35. Tobias PS, McAdam KPWJ, Soldau K, et al: Control of lipopolysaccharide-high density lipoprotein interactions by an acute-phase reactant in human serum. Infect Immun 1985; 50:73-76
36. Calvano SE, Thompson WA, Marra MN, et al: Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 1994; 129:220-226
37. Setrakian JC, Yee J, Christou NV: Reduced tumor necrosis factor α production in lipopolysaccharide-treated whole blood from patients in the intensive care unit. Arch Surg 1994; 129:187-192
38. Ettinger WH, Varma VK, Sorci-Thomas M, et al: Cytokines decrease apolipoprotein accumulation in medium from HEP G2 cells. Arterioscler Thromb 1994; 14:8-13
39. Vitols S, Bjorkholm M, Gahrton G, et al: Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: Evidence from studies in patients with leukaemia. Lancet 1985; ii:1150-1154
40. Kawakami M, Cerami A: Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981; 154:631-639
41. Kaufmann RL, Matson CF, Beisel WR: Hypertriglyceridemia produced by endotoxin: Role of impaired triglyceride disposal mechanisms. J Infect Dis 1976; 133:548-555
42. Feingold KR, Staprans I, Memon RA, et al: Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: Low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992; 33:1765-1776
43. Krauss RM, Grunfeld C, Doerrler WT, et al: Tumor necrosis factor acutely increases plasma levels of very lowdensity lipoproteins of normal size and composition. Endocrinology 1990; 127: 1016-1021